000			na a22 4500
999			_c11239 _d11239
003			PC11239
005			20190610140001.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aCoronado, C. _92563 _eOncología Médica
100			_aCortés-Funes Castro, Hernán _91181 _eOncología Médica
100			_aLópez Martín, Ana _9737 _eOncología Médica
100			_aPaz-Ares Rodríguez, Luis _91811 _eOncología Médica
245	0	0	_aPhase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors. _h[artículo]
260			_bCancer chemotherapy and pharmacology, _c2013
300			_a72(1):75-83.
500			_aFormato Vancouver: Salazar R, Cortés-Funes H, Casado E, Pardo B, López-Martín A, Cuadra C et al. Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013 Jul;72(1):75-83.
501			_aPMID: 23645288
504			_aContiene 18 referencias
520			_aPURPOSE: Kahalalide F (KF) is a dehydroaminobutyric acid-containing peptide from marine origin with activity against several human malignant cell lines. This dose-escalating phase I clinical trial evaluated the maximum tolerated dose (MTD), and the recommended dose for further phase II studies (RD) of weekly KF given as a prolonged (3- to 24-h) intravenous (i.v.) infusion.
710			_9303 _aServicio de Oncología Médica
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc11239.pdf _ySolicitar documento
942			_n0 _2ddc _cART